Gynecologic Oncology Consult

What is HIPEC?


 

Dr. Rossi is an assistant professor in the division of gynecologic oncology at the University of North Carolina at Chapel Hill.

References

1. Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.

2. Helm CW et al. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008;98(4):283-90.

3. Glehen O et al. Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion. J Surg Oncol. 2008;98(4):242-6.

4. Kusamura S et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98(4):247-52.

5. Kusamura S et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol. 2007;14(9):2550-8.

6. van Driel WJ et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan;378(3):230-240.

Pages

Recommended Reading

VIDEO: Pelvic radiation surpasses brachytherapy/chemo for early endometrial cancer
MDedge Hematology and Oncology
Oncologist-led BRCA mutation testing and counseling may reduce wait times for women with ovarian cancer
MDedge Hematology and Oncology
Combined PARP, checkpoint inhibitor regimens show ovarian cancer activity
MDedge Hematology and Oncology
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
MDedge Hematology and Oncology
VIDEO: Cervical cancer laparotomy outperforms minimally invasive surgery
MDedge Hematology and Oncology
VIDEO: Interventions target opioid overprescribing after gynecologic surgery
MDedge Hematology and Oncology
Residual single-site ovarian cancer surpasses multisite outcomes
MDedge Hematology and Oncology
Trastuzumab plus chemo shows efficacy for high HER2 endometrial cancer
MDedge Hematology and Oncology
VIDEO: Indocyanine green finds more sentinel lymph nodes
MDedge Hematology and Oncology
Disproportionately low U.S. research funding targets gynecologic cancers
MDedge Hematology and Oncology